Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Sangui BioTech International Inc., US80105B1017

Sangui BioTech International Inc., US80105B1017

29.09.2021 - 11:09:26

Sangui BioTech International Inc.: - Sales of USD 65,582 in fiscal year 2021 - Reduction of the operating loss


Sangui BioTech: - Sales of USD 65,582 in fiscal year 2021 - Reduction of the operating loss ?

Hamburg, September, 29 2021: In the fiscal year 2021 (01/07/2020 to 30/06/2021) Sangui BioTech International, Inc. achieved revenues from royalty income and product sales of USD 65,582. In the same period of the previous year the comparable revenue amounted to USD 28,915. Due to increased revenues of the wound spray Granulox, the resulting royalty income of 2021 increased by 127% compared to previous year.

As operating expenses increased USD 6,414 or 3% to USD 216,723 during the period, operating loss decreased USD 30,256 to USD 151,138 from the prior year.

Due to the lower exchange rate of the US dollar to the EURO compared to the previous year's reporting date and the resulting increased exchange rate loss from the valuation of loans denominated in EURO, the loss of the twelve month period increased by USD 5,184 to USD 203,7310.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact: Sangui Biotech International, Inc. Thomas Striepe Fax: +49 (40)46093120 e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

29.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de


@ dgap.de